The detailed knowledge of the mechanisms of action of HDAC inhibitors in prostate cancers can be applied for combination therapies together with other suitable drugs against prostate cancer to achieve improved anticancer responses [Table 3, Figures 1 and 3]. Here, HDAC9 is linked to prostate carcinoma.